Category: T2 Biosystems Inc.
Imaging3 names Dane Medley as its new CEO, replacing the outgoing Dean James in the corner office.
Imaging3 (OTC:IMGG) said Dane Medley will replace Dean James as chairman & CEO.
Medley's résumé includes time with Xerox (NYSE:XRX) and Sharp Electronics. Medley also started 360 Dynamic Technology, a privately owned startup that provides sales and service for office products/technology.
T2 Biosystems launches a clinical trial of its T2Candida test to detect Candida, a leading cause of hospital-acquired infections that can lead to deadly cases of sepsis.
T2 Biosystems said it's launched a clinical trial of its MR-based test for a fungus that's a common cause of deadly hospital-acquired infections.
The Lexington, Mass.-based company said it plans to use the study results to back a regulatory submission for the T2Candida test for the Candida fungus, estimated to cause some 100,000 cases of candidemia each year in the U.S.
T2 Biosystems CEO John McDonough tells MassDevice.com why the medical device company's MRI-based diagnostics tool could revolutionize diagnostics and save millions of lives in the process.
When MassDevice.com last spoke with T2 Biosystems CEO John McDonough, in August 2009, the 22-worker firm was still developing a novel use for MRI technology – diagnostics.
T2's device uses magnetic resonance to identify pathogens in just about any kind of sample, eliminating the need for time-consuming blood culture work.
Biolase CEO Federico Pignatelli, who made waves with his commitment to a $1 salary, denies rumors that he is stepping down.
Biolase (NSDQ:BLTI) issued a message to concerned investors, quashing rumors of CEO Federico Pignatelli's imminent departure and asserting his continued leadership of the dental laser company.
T2 Biosystems reels in a $40 million Series E round for its MR-based molecular diagnostic test for the Candida fungus, a leading cause of hospital-acquired infections.
T2 Biosystems, which is developing a diagnostic device that uses magnetic resonance technology to deliver nearly instant test results, said it raised a $40 million Series E round it plans to use for its T2Candida test for a common cause of hospital-acquired infections.
T2 raises $24 million in a series D financing round to prepare for an FDA bid in the second half of 2012.
T2 Biosystems Inc. closed a $23 million series D funding round this week, which will support its ongoing development and clinical trials and the company inches closer to a FDA bid and commercialization.
This latest round was led by new investor Aisling Capital LLC, and joined by existing investors Flagship Ventures, Polaris Venture Partners, Flybridge Capital Partners, Physic Ventures, Partners Healthcare, Arcus Ventures, RA Capital, Camros Capital and WS Investments.
In conjunction with the funding, Aisling Capital principal Dr. Josh Bilenker joins T2's board of directors.
T2 Biosystems Inc.'s MR-based benchtop diagnostic device detects a deadly bloodstream infection in two hours, according to study results released today, meaning it could cut the mortality rate from Candida fungal blood infections by 73 percent.
T2 Biosystems Inc. says its new blood test for the cause of a deadly blood pathogen could help make huge reductions in the mortality rate in people infected with the fungus Candida.